Desloratadine, an antihistamine used to treat allergic conditions such as allergic rhinitis and chronic urticaria, was developed in the 1990s and approved for medical use in the early 2000s. Its history is marked by its effectiveness as a non-sedating antihistamine with a favorable safety profile. Desloratadine, a selective histamine H1 receptor antagonist, was approved in the United States in 2001 and is widely used as a once-daily therapy for allergy relief. Its development focused on improving upon earlier antihistamines by reducing sedation and enhancing duration of action, leading to its inclusion in numerous allergy treatment regimens.
BRAND NAMES
Clarinex
Aerius
Desalex
MECHANISM OF ACTION
Desloratadine is a selective, long-acting peripheral histamine H1 receptor antagonist that exerts its effect by blocking the action of histamine, a key mediator released during allergic reactions. By competitively inhibiting histamine at H1 receptors, it prevents the cascade of allergic symptoms such as vasodilation, increased vascular permeability, itching, and mucus secretion.
PHARMACOKINETICS
Absorption
Desloratadine is well absorbed after oral administration, with measurable plasma concentrations typically detected within 30 minutes. Peak plasma levels are usually reached within approximately 3 hours
Distribution
Desloratadine has a moderate volume of distribution, indicating that it is distributed beyond the vascular compartment into body tissues. It is extensively bound to plasma proteins (approximately 80–90%), which influences its distribution profile.
Metabolism
Desloratadine is extensively metabolized in the liver to form its primary active metabolite, 3-hydroxydesloratadine, which is further conjugated mainly by glucuronidation.
Elimination
Desloratadine is eliminated from the body through both renal and fecal excretion, primarily as its metabolites, with only a small portion excreted unchanged. Its elimination half-life is approximately 20 to 30 hours, supporting once-daily dosing.
PHARMACODYNAMICS
Desloratadine is a selective, long-acting H1 receptor antagonist that competitively inhibits the action of histamine at peripheral H1 receptors. By blocking histamine binding, it prevents the cascade of allergic responses, including vasodilation, increased vascular permeability, edema, itching, and mucus secretion.
ADMINISTRATION
Desloratadine is administered orally, available in tablet, orally disintegrating tablet, and syrup formulations, allowing flexibility for adults, children, and patients with swallowing difficulties. The drug is typically taken once daily, with or without food, due to its long half-life and sustained action.
DOSAGE AND STRENGTH
Desloratadine is available in multiple formulations and strengths to accommodate different age groups and clinical needs. For adults and children 12 years and older, the standard dose is 5 mg once daily, usually as a tablet or syrup.
DRUG INTERACTIONS
Desloratadine has a relatively low potential for drug–drug interactions due to its minimal metabolism via major cytochrome P450 enzymes. Concomitant administration with common medications, such as antacids, azithromycin, or pseudoephedrine, does not significantly alter its pharmacokinetics or efficacy.
FOOD INTERACTIONS
Desloratadine can be taken with or without food, as its absorption and effectiveness are not significantly affected by meals. Unlike some medications whose bioavailability is altered by high-fat or large meals, desloratadine maintains consistent plasma levels regardless of food intake.
CONTRAINDICATIONS
Desloratadine is contraindicated in individuals with a known hypersensitivity to desloratadine, loratadine, or any component of the formulation. It should not be administered to patients who have experienced allergic reactions to similar H1-antihistamines, as this may precipitate severe hypersensitivity.
SIDE EFFECTS
Headache
Dry mouth
Fatigue or mild drowsiness
Nausea
Dizziness
Abdominal discomfort
Rare hypersensitivity reactions
Very low risk of sedation or impaired cognition.
OVER DOSAGE
Desloratadine has a wide therapeutic index, and cases of overdose are generally rareand mild. Symptoms of overdosage may include drowsiness, headache, rapid heartbeat, or dry mouth. Severe toxic effects are uncommon. Management is primarily supportive and symptomatic, as there is no specific antidote.
TOXICITY
Desloratadine exhibits low toxicity in both preclinical and clinical studies, even at doses higher than those recommended therapeutically. It rarely causes serious adverse effects, and the risk of life-threatening reactions is minimal. Toxic effects, when they occur, are generally limited to mild central nervous system symptoms such as headache, fatigue, or mild sedation, and gastrointestinal disturbances like nausea or dry mouth.
